Boots charts Clearasil course
This article was originally published in The Rose Sheet
Executive Summary
UK-based Boots will devote additional $171 mil. (?1=$1.42) to support its three "core" brands, including Clearasil, Strepsils medicated lozenges and Nuraphen analgesics, over the next four years, company says. Increased support is part of effort to boost Boots' profit from organic growth from $84.9 mil. to $142.5 mil. within four years. Additional support will be split between marketing and new product development, company says. New ads for Clearasil, designed by Grey Global Group, will debut in the U.S. in May and feature a more "contemporary" perspective on acne, according to Boots. Four new Clearasil products also are slated to bow stateside later this year, according to the firm. Boots acquired Clearasil from Procter & Gamble in 2000 (1"The Rose Sheet" Oct. 23, 2000, p. 3)...